Tools

LEADER 03561nam 2200625 i 4500

001 on1552582837;

005 20260127093945.0;

006 m o d f ;

007 cr bn||||a||||;

008 251119s2025 dcu ob f000 0 eng c;

024 8 a| 55-663q| (GPO jacket number);

035 a| (Sirsi) o1552582837;

035 a| (OCoLC)1552582837;

042 a| pcc;

043 a| a-cc---a| n-us---;

049 a| ERE#;

074 a| 1019-C-01 (online);

086 0 a| Y 4.C 73/8:118-30;

088 a| Serial no. 118-30 (United States. Congress. House. Committee on Energy and Commerce);

245 14 a| The biosafety of risky research :b| examining if science is outpacing policy and safety : hearing before the Subcommittee on Oversight and Investigations of the Committee on Energy and Commerce, House of Representatives, One Hundred Eighteenth Congress, first session, April 27, 2023.;

264 1 a| Washington :b| U.S. Government Publishing Office,c| 2025.;

300 a| 1 online resource (v, 113 pages);

336 a| textb| txt2| rdacontent;

337 a| computerb| c2| rdamedia;

338 a| online resourceb| cr2| rdacarrier;

500 a| This is a publication issued by the United States federal government or produced with federal funds.;

500 a| "Serial no. 118-30.";

504 a| Includes bibliographical references.;

511 0 a| Hearing witnesses: Rocco Casagrande, Ph.D., Board Chair, Gryphon Scientific; Gregory D. Koblentz, Ph.D., Associate Professor and Director, Biodefense Graduate Programs, George Mason University; Andy Pekosz, Ph.D., Professor of Molecular Microbiology and Immunology, Johns Hopkins University Bloomberg School of Public Health; Robert J. Hawley, Ph.D., Consultant, Biological Safety and Security.;

518 a| Date of hearing: 2023-04-27.;

588 a| Description based on online resource, PDF version; title from title page (GovInfo, viewed Nov. 19, 2025).;

500 a| In scope of the U.S. Government Publishing Office Cataloging and Indexing Program (C&I) and Federal Depository Library Program (FDLP).;

650 0 a| Pathogenic virusesx| Security measuresz| United States.=| ^A1273032;

650 0 a| Pathogenic virusesx| Government policyz| United States.=| ^A1273032;

650 0 a| COVID-19 (Disease)z| United States.=| ^A1407776;

650 0 a| COVID-19 Pandemic, 2020-2023z| United States.=| ^A1418885;

650 0 a| Virologyx| Researchz| United States.=| ^A77071;

650 7 a| Health.2| cgpa;

650 7 a| Commerce.2| cgpa;

655 7 a| Legislative hearings.2| lcgft;

776 08 i| Print version:a| United States. Congress. House. Committee on Energy and Commerce. Subcommittee on Oversight and Investigations.t| Biosafety of risky researchw| (OCoLC)1552582601;

776 08 i| Print version:;

856 40 u| https://purl.fdlp.gov/GPO/gpo2494757| 0;

856 4 z| Address at time of PURL creationu| https://www.govinfo.gov/content/pkg/CHRG-118hhrg55663/pdf/CHRG-118hhrg55663.pdf;

949 a| Click on web addressw| asish| joyner94o| jjlm;

994 a| C0b| GPO;

955 a| bca68 20251119b| 20251119;

922 a| BIBCONEWb| 20251119;

596 a| 1;

998 a| 6653296;

999 a| CLICK ON WEB ADDRESSw| ASISc| 1i| 6653296-1001l| JNETm| JOYNERr| Ys| Yt| JNE1DOu| 12/3/2025x| EDOCUMENTz| JERESOURCEo| .STAFF. jjlm;

The biosafety of risky research : examining if science is outpacing policy and safety : hearing before the Subcommittee on Oversight and Investigations of the Committee on Energy and Commerce, House of Representatives, One Hundred Eighteenth Congress, first session, April 27, 2023.

Author/creator	United States
Format	Electronic
Publication	Washington : U.S. Government Publishing Office, 2025.
Description	1 online resource (v, 113 pages)
Supplemental Content	https://purl.fdlp.gov/GPO/gpo249475
Supplemental Content	Address at time of PURL creation
Subjects	Pathogenic viruses--Security measures. --United States. Pathogenic viruses--Government policy. --United States. COVID-19 (Disease)--United States. Viruses--Research. --China. --Wuhan Shi. COVID-19 Pandemic, 2020-2023--United States. Virology--Research. --China. --Wuhan Shi. Virology--Research. --United States.

General note	This is a publication issued by the United States federal government or produced with federal funds.
General note	"Serial no. 118-30."
General note	In scope of the U.S. Government Publishing Office Cataloging and Indexing Program (C&I) and Federal Depository Library Program (FDLP).
Bibliography note	Includes bibliographical references.
Performer	Hearing witnesses: Rocco Casagrande, Ph.D., Board Chair, Gryphon Scientific; Gregory D. Koblentz, Ph.D., Associate Professor and Director, Biodefense Graduate Programs, George Mason University; Andy Pekosz, Ph.D., Professor of Molecular Microbiology and Immunology, Johns Hopkins University Bloomberg School of Public Health; Robert J. Hawley, Ph.D., Consultant, Biological Safety and Security.
Date/time/place of a event note	Date of hearing: 2023-04-27.
Source of description	Description based on online resource, PDF version; title from title page (GovInfo, viewed Nov. 19, 2025).
Issued in other form	Print version: United States. Congress. House. Committee on Energy and Commerce. Subcommittee on Oversight and Investigations. Biosafety of risky research
Issued in other form	Print version:
Genre/form	Legislative hearings.
Standard identifier#	55-663 (GPO jacket number)
Technical rpt number	Serial no. 118-30 (United States. Congress. House. Committee on Energy and Commerce)
GPO item number	1019-C-01 (online)
Govt. docs number	Y 4.C 73/8:118-30

The biosafety of risky research : examining if science is outpacing policy and safety : hearing before the Subcommittee on Oversight and Investigations of the Committee on Energy and Commerce, House of Representatives, One Hundred Eighteenth Congress, first session, April 27, 2023.

Click here for more information about this title